SPYRE THERAPEUTICS INC (SYRE) Stock Price, Quote, News and Overview
NASDAQ:SYRE - Nasdaq - US00773J2024 - Common Stock - Currency: USD
SYRE Quote, Performance and Key Statistics
16.35
+0.06 (+0.37%)
The current stock price of SYRE is 16.35 USD. In the past month the price increased by 8.93%. In the past year, price decreased by -48.05%.
SYRE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18 | 326.52B | ||
| AMGN | AMGEN INC | 14.25 | 159.09B | ||
| GILD | GILEAD SCIENCES INC | 13.99 | 134.69B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 117.74B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.31 | 58.90B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 41.79B | ||
| ARGX | ARGENX SE - ADR | 98.46 | 34.57B | ||
| ONC | BEONE MEDICINES LTD-ADR | 7.47 | 31.59B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.18B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.56B | ||
| INSM | INSMED INC | N/A | 19.50B | ||
| NTRA | NATERA INC | N/A | 19.20B |
Related stock screener links
About SYRE
Company Profile
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. The company is headquartered in Waltham, Massachusetts and currently employs 65 full-time employees. The company went IPO on 2016-04-07. Its pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, SPY230, SPY002, SPY001, and SPY120. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a preclinical-stage program designed to bind to Interleukin 23 (IL-23) and incorporates half-life extending modifications.
Company Info
SPYRE THERAPEUTICS INC
221 Crescent Street, Suite 105
Waltham MASSACHUSETTS US
Employees: 65
Phone: 16176515940.0
SPYRE THERAPEUTICS INC / SYRE FAQ
What is the stock price of SPYRE THERAPEUTICS INC today?
The current stock price of SYRE is 16.35 USD. The price increased by 0.37% in the last trading session.
What is the ticker symbol for SPYRE THERAPEUTICS INC stock?
The exchange symbol of SPYRE THERAPEUTICS INC is SYRE and it is listed on the Nasdaq exchange.
On which exchange is SYRE stock listed?
SYRE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SPYRE THERAPEUTICS INC stock?
18 analysts have analysed SYRE and the average price target is 55.42 USD. This implies a price increase of 238.96% is expected in the next year compared to the current price of 16.35. Check the SPYRE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SPYRE THERAPEUTICS INC worth?
SPYRE THERAPEUTICS INC (SYRE) has a market capitalization of 986.72M USD. This makes SYRE a Small Cap stock.
How many employees does SPYRE THERAPEUTICS INC have?
SPYRE THERAPEUTICS INC (SYRE) currently has 65 employees.
What are the support and resistance levels for SPYRE THERAPEUTICS INC (SYRE) stock?
SPYRE THERAPEUTICS INC (SYRE) has a support level at 15.77 and a resistance level at 16.88. Check the full technical report for a detailed analysis of SYRE support and resistance levels.
Is SPYRE THERAPEUTICS INC (SYRE) expected to grow?
The Revenue of SPYRE THERAPEUTICS INC (SYRE) is expected to decline by -100% in the next year. Check the estimates tab for more information on the SYRE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SPYRE THERAPEUTICS INC (SYRE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SYRE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SYRE, evaluating the profitability, health, valuation and growth aspects
- SPYRE THERAPEUTICS INC (SYRE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SPYRE THERAPEUTICS INC (SYRE) Sales and EPS estimates to see what analysts future expectations are.
- SPYRE THERAPEUTICS INC (SYRE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SPYRE THERAPEUTICS INC (SYRE) Insider and Institutional Ownership to learn about the owners and their transactions.
- SPYRE THERAPEUTICS INC (SYRE) Stock Chart to make your own analysis
- SPYRE THERAPEUTICS INC (SYRE) Latest news and press-releases to stay up to date.
Does SPYRE THERAPEUTICS INC (SYRE) stock pay dividends?
SYRE does not pay a dividend.
When does SPYRE THERAPEUTICS INC (SYRE) report earnings?
SPYRE THERAPEUTICS INC (SYRE) will report earnings on 2025-07-31, after the market close.
What is the Price/Earnings (PE) ratio of SPYRE THERAPEUTICS INC (SYRE)?
SPYRE THERAPEUTICS INC (SYRE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.63).
What is the Short Interest ratio of SPYRE THERAPEUTICS INC (SYRE) stock?
The outstanding short interest for SPYRE THERAPEUTICS INC (SYRE) is 25.55% of its float. Check the ownership tab for more information on the SYRE short interest.
SYRE Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to SYRE. When comparing the yearly performance of all stocks, SYRE is a bad performer in the overall market: 87.27% of all stocks are doing better.
SYRE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SYRE. No worries on liquidiy or solvency for SYRE as it has an excellent financial health rating, but there are worries on the profitability.
SYRE Financial Highlights
Over the last trailing twelve months SYRE reported a non-GAAP Earnings per Share(EPS) of -3.63. The EPS increased by 93.53% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -34.19% | ||
| ROE | -40.17% | ||
| Debt/Equity | 0 |
SYRE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 89% to SYRE. The Buy consensus is the average rating of analysts ratings from 18 analysts.
For the next year, analysts expect an EPS growth of 26.82% and a revenue growth -100% for SYRE